These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

657 related articles for article (PubMed ID: 26139243)

  • 1. The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.
    Vangamudi B; Paul TA; Shah PK; Kost-Alimova M; Nottebaum L; Shi X; Zhan Y; Leo E; Mahadeshwar HS; Protopopov A; Futreal A; Tieu TN; Peoples M; Heffernan TP; Marszalek JR; Toniatti C; Petrocchi A; Verhelle D; Owen DR; Draetta G; Jones P; Palmer WS; Sharma S; Andersen JN
    Cancer Res; 2015 Sep; 75(18):3865-3878. PubMed ID: 26139243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
    Karnezis AN; Wang Y; Ramos P; Hendricks WP; Oliva E; D'Angelo E; Prat J; Nucci MR; Nielsen TO; Chow C; Leung S; Kommoss F; Kommoss S; Silva A; Ronnett BM; Rabban JT; Bowtell DD; Weissman BE; Trent JM; Gilks CB; Huntsman DG
    J Pathol; 2016 Feb; 238(3):389-400. PubMed ID: 26356327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SWI/SNF Complex-deficient Undifferentiated/Rhabdoid Carcinomas of the Gastrointestinal Tract: A Series of 13 Cases Highlighting Mutually Exclusive Loss of SMARCA4 and SMARCA2 and Frequent Co-inactivation of SMARCB1 and SMARCA2.
    Agaimy A; Daum O; Märkl B; Lichtmannegger I; Michal M; Hartmann A
    Am J Surg Pathol; 2016 Apr; 40(4):544-53. PubMed ID: 26551623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation.
    Wilson BG; Helming KC; Wang X; Kim Y; Vazquez F; Jagani Z; Hahn WC; Roberts CW
    Mol Cell Biol; 2014 Mar; 34(6):1136-44. PubMed ID: 24421395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SMARCA2-deficiency confers sensitivity to targeted inhibition of SMARCA4 in esophageal squamous cell carcinoma cell lines.
    Ehrenhöfer-Wölfer K; Puchner T; Schwarz C; Rippka J; Blaha-Ostermann S; Strobl U; Hörmann A; Bader G; Kornigg S; Zahn S; Sommergruber W; Schweifer N; Zichner T; Schlattl A; Neumüller RA; Shi J; Vakoc CR; Kögl M; Petronczki M; Kraut N; Pearson MA; Wöhrle S
    Sci Rep; 2019 Aug; 9(1):11661. PubMed ID: 31406271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors - a review of patent literature from 2019-30 June 2023.
    Reichl KD; Lee ECY; Gopalsamy A
    Expert Opin Ther Pat; 2024 Mar; 34(3):159-169. PubMed ID: 38578210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens.
    Herpel E; Rieker RJ; Dienemann H; Muley T; Meister M; Hartmann A; Warth A; Agaimy A
    Ann Diagn Pathol; 2017 Feb; 26():47-51. PubMed ID: 28038711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SMARCA2 Is a Novel Interactor of NSD2 and Regulates Prometastatic
    Chong PSY; Chooi JY; Lim JSL; Toh SHM; Tan TZ; Chng WJ
    Cancer Res; 2021 May; 81(9):2332-2344. PubMed ID: 33602783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.
    Oike T; Ogiwara H; Tominaga Y; Ito K; Ando O; Tsuta K; Mizukami T; Shimada Y; Isomura H; Komachi M; Furuta K; Watanabe S; Nakano T; Yokota J; Kohno T
    Cancer Res; 2013 Sep; 73(17):5508-18. PubMed ID: 23872584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers.
    Hoffman GR; Rahal R; Buxton F; Xiang K; McAllister G; Frias E; Bagdasarian L; Huber J; Lindeman A; Chen D; Romero R; Ramadan N; Phadke T; Haas K; Jaskelioff M; Wilson BG; Meyer MJ; Saenz-Vash V; Zhai H; Myer VE; Porter JA; Keen N; McLaughlin ME; Mickanin C; Roberts CW; Stegmeier F; Jagani Z
    Proc Natl Acad Sci U S A; 2014 Feb; 111(8):3128-33. PubMed ID: 24520176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours.
    Rao Q; Xia QY; Wang ZY; Li L; Shen Q; Shi SS; Wang X; Liu B; Wang YF; Shi QL; Ma HH; Lu ZF; He Y; Zhang RS; Yu B; Zhou XJ
    Histopathology; 2015 Jul; 67(1):121-9. PubMed ID: 25496315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2:
    Chan-Penebre E; Armstrong K; Drew A; Grassian AR; Feldman I; Knutson SK; Kuplast-Barr K; Roche M; Campbell J; Ho P; Copeland RA; Chesworth R; Smith JJ; Keilhack H; Ribich SA
    Mol Cancer Ther; 2017 May; 16(5):850-860. PubMed ID: 28292935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel structural-related analogs of PFI-3 (SRAPs) that target the BRG1 catalytic subunit of the SWI/SNF complex increase the activity of temozolomide in glioblastoma cells.
    He Y; Yang C; Wang Y; Sacher JR; Sims MM; Pfeffer LM; Miller DD
    Bioorg Med Chem; 2022 Jan; 53():116533. PubMed ID: 34863065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chromatin remodeling defects and cancer: the SWI/SNF example].
    Bourdeaut F; Bièche I
    Bull Cancer; 2012 Dec; 99(12):1133-40. PubMed ID: 23222069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Bromodomains of the mammalian SWI/SNF (mSWI/SNF) ATPases Brahma (BRM) and Brahma Related Gene 1 (BRG1) promote chromatin interaction and are critical for skeletal muscle differentiation.
    Sharma T; Robinson DCL; Witwicka H; Dilworth FJ; Imbalzano AN
    Nucleic Acids Res; 2021 Aug; 49(14):8060-8077. PubMed ID: 34289068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Bromodomain Inhibitor PFI-3 Sensitizes Cancer Cells to DNA Damage by Targeting SWI/SNF.
    Lee D; Lee DY; Hwang YS; Seo HR; Lee SA; Kwon J
    Mol Cancer Res; 2021 May; 19(5):900-912. PubMed ID: 33208498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent on activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex.
    Wang X; Sansam CG; Thom CS; Metzger D; Evans JA; Nguyen PT; Roberts CW
    Cancer Res; 2009 Oct; 69(20):8094-101. PubMed ID: 19789351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SWI/SNF complexes are required for full activation of the DNA-damage response.
    Smith-Roe SL; Nakamura J; Holley D; Chastain PD; Rosson GB; Simpson DA; Ridpath JR; Kaufman DG; Kaufmann WK; Bultman SJ
    Oncotarget; 2015 Jan; 6(2):732-45. PubMed ID: 25544751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors - a review of patent literature from 2019-June 2023.
    Lee ECY; Reichl KD; Gopalsamy A
    Expert Opin Ther Pat; 2024 Apr; 34(4):211-229. PubMed ID: 38742308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of SWI/SNF chromatin remodeling factor subunits modulates cisplatin cytotoxicity.
    Kothandapani A; Gopalakrishnan K; Kahali B; Reisman D; Patrick SM
    Exp Cell Res; 2012 Oct; 318(16):1973-86. PubMed ID: 22721696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.